疫苗企业出海

Search documents
疫苗ETF鹏华(159657)涨近2%实现3连涨,智飞生物流感疫苗实现重大突破
Xin Lang Cai Jing· 2025-08-13 07:45
Group 1 - The National Vaccine and Biotechnology Index (980015) rose by 1.92% as of August 13, 2025, with significant gains from constituent stocks such as Zhaoyan New Drug (603127) up 9.16%, Changshan Pharmaceutical (300255) up 7.86%, and WuXi AppTec (603259) up 7.24% [1] - Zhifei Biological's subsidiary achieved a major breakthrough by completing the first nationwide vaccination of its quadrivalent influenza vaccine in Hefei, Anhui Province [1] - Haitong International Securities noted that while overseas revenue for Chinese vaccine companies remains relatively low, more companies are actively expanding into international markets, with a steady increase in the number of vaccine product pre-certifications [1] Group 2 - The top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) as of July 31, 2025, include Fosun Pharma (600196), Changchun High-tech (000661), and Zhifei Biological (300122), collectively accounting for 64.94% of the index [2] - The Vaccine ETF Penghua (159657) closely tracks the National Vaccine and Biotechnology Index, which consists of 50 companies involved in the biotechnology industry, reflecting the overall performance of quality listed companies in the sector [1]